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Foreword 
 
 
Malignant and non-malignant cells can significantly differ in their way to metabolize glucose. 
While normal differentiated cells tend to fully oxidize glucose by the coupling of glycolysis 
and oxidative phosphorylation, some cancer cells adopt glycolysis as a main mode of 
energy production even in the presence of oxygen. Intense research has led to a globally 
accepted hypothesis, considering that aerobic glycolysis (also termed the “Warburg Effect”) 
is beneficial for energy production and proliferation. It has already attracted major interest as 
it is hoped that drugs targeting glycolysis will be effective in decreasing cancer progression. 
Demystifying mechanisms by which cancer cells switch to a constitutive glycolytic phenotype 
is of paramount importance in order to develop efficient therapeutic strategies. It also allows 
understanding resistance phenomena occurring in some cancer patients. Pioneering studies 
on cancer metabolism suggested that enhanced glycolysis was caused by irreversible 
impairment in mitochondrial respiration. Since then, this hypothesis has been repeatedly 
refuted to some exceptions; and functional mitochondrial activity was reported in cancer 
cells.  
To date, clinical studies on metabolism-targeting drugs have provided encouraging data; but 
efforts in increasing treatment efficacy, reducing side-effects and avoiding resistance are still 
needed. In this regard, combination of treatments with other modalities is an important 
avenue for future clinical development. Hypoxia is particularly considered as a tumor feature 
to overcome, as it induces resistance to chemo- and radiotherapy. For this reason, 
molecules that alter oxygen consumption by cancer cells and/or increase their supply of 
oxygen can be advantageous.  
 
In chapter 1, several concepts of cancer metabolism are described and recent advances in 
drug development are highlighted. Current strategies that tackle glycolysis are first depicted, 
with a particular focus on the recently discovered molecule dichloroacetate (DCA). Then, the 
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role of mitochondria in supporting tumor growth is detailed and drugs inhibiting mitochondrial 
oxidative metabolism are considered. Emphasis is given to approaches consisting in 
reducing hypoxia at the time of irradiation by decreasing cellular oxygen consumption and/or 
increasing oxygen supply to cancer cells. The end of this chapter is dedicated to the 
gaseous molecule hydrogen sulfide (H2S). It has recently been identified in mammals where 
it has been found to be implicated in various physiological and pathological processes, 
including cancer. We give highlights on how H2S interacts with mitochondria, known as its 
primary target, and discuss its possible role in cancer.  
 
In chapter 2, specific aims of the thesis are described. 
 
Chapter 3 reports findings on the mechanisms by which enhanced glucose metabolization 
through glycolysis favors cancer cells proliferation. Effects of metabolic modulations are 
described and new insights on the efficacy of DCA are presented. 
 
In chapter 4, the effects of the H2S donor NaHS in cancer therapy are investigated. Two 
approaches are considered: NaHS in association with radiotherapy or in monotherapy. 
 
Chapter 5 summarizes and discusses the principal findings. This section also presents 
future directions and the potential impact on clinical development of metabolism-targeting 
strategies. 
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Chapter 1 Introduction 
 
I.  Metabolism of cancer cells - The Warburg effect 
Deregulation of metabolic pathways is emerging as an important hallmark of cancer 
(Hanahan and Weinberg, 2011). It was first described by Warburg in the early 20th century 
that some tumor cells exhibit high levels of glycolysis despite the presence of abundant 
oxygen (O2), leading Warburg to propose the hypothesis according to which cancer arises 
from impaired mitochondrial metabolism (Warburg, 1956). Since then, the Warburg 
hypothesis on the origin of cancer has largely proven incorrect, with the demonstration that 
mitochondria most generally have functional oxidative activity in tumor cells (Nakashima et 
al., 1984; Zu and Guppy, 2004). Nevertheless, constitutive upregulation of glycolysis is a 
common feature of many tumor types, so that it is now exploited as a diagnostic tool and a 
promising approach to treat malignant lesions (Gatenby and Gillies, 2004). 
1. Definition 
In normal differentiated cells, one molecule of glucose is converted to two molecules of 
pyruvate by a sequence of ten enzymatic reactions that take place in the cytosol. In addition 
to the generation of pyruvate, glycolysis produces two molecules of ATP, two molecules of 
water, two molecules of reduced nicotinamide adenine dinucleotide (NADH) and two protons 
(H+). In the presence of O2, glycolysis is coupled to the tricarboxylic acid (TCA) cycle where 
pyruvate is oxidatively metabolized to CO2; producing additional NADH molecules, H
+, 
guanosine triphosphate (GTP) and reduced flavin adenine dinucleotide (FADH2). Reductive 
equivalents produced by glycolysis (that enter into mitochondria via the malate-aspartate 
shuttle) and by the TCA cycle serve as electron donors to the mitochondrial electron 
transport chain (ETC). By passing through complexes I to IV, transported electrons create a 
gradient of protons across the inner mitochondrial membrane. They ultimately react with O2 
to produce water. When the protons that accumulate in the intermembrane space are 
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transferred back to the mitochondrial matrix by ATP synthase, up to 36 molecules of ATP 
are produced per molecule of glucose, a process known as oxidative phosphorylation 
(OXPHOS) (Rolfe and Brown, 1997). When the O2 supply is limited, pyruvate is converted to 
lactate by the lactate dehydrogenase (LDH) enzyme rather than being used in the TCA cycle 
and glycolysis becomes the primary source for ATP production (anaerobic glycolysis) (Rolfe 
and Brown, 1997) (figure 1). Compared to normal differentiated cells, some cancer cells can 
consume glucose at a higher rate and convert pyruvate to lactate even in the presence of O2 
(aerobic glycolysis or the “Warburg Effect”) (Vander Heiden et al., 2009). It has however 
been demonstrated that some proliferating normal cells, such as stem cells (Folmes et al., 
2011) and activated immune cells (Hedeskov, 1968), can also exhibit a highly glycolytic 
metabolism (figure 1). 
 
 
 
Figure 1: In the presence of oxygen, normal differentiated cells couple glycolysis to 
oxidative phosphorylation for optimal ATP synthesis. Compared to normal differentiated 
cells, some cancer cells exhibit a constitutive upregulation of glycolysis even in the presence 
of an adequate oxygen supply (aerobic glycolysis or the “Warburg Effect”). This particular 
phenotype is characterized by elevated glucose consumption and lactate production and is 
also found in some rapidly dividing normal cells. 
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The Warburg Effect counteracts the Pasteur Effect that operates in most mammalian 
cells and finely tunes cell metabolism in function of the local O2 concentration (Wu and 
Racker, 1959). In normoxia, key glycolytic enzymes of normal cells (hexokinase (HK) -1, 
phosphofructokinase (PFK) -1, pyruvate kinase (PK) -1) are allosterically repressed by 
energetic metabolites (ATP, citrate, glucose-6-phosphate). Conversely, when the O2 supply 
is compromised, the glycolytic flux is accelerated because of the decreased levels of ATP 
and citrate produced oxidatively (Porporato et al., 2011). To keep an elevated glycolytic flux, 
Warburg-phenotype cancer cells develop mechanisms to escape the Pasteur Effect. This 
can be achieved by actively consuming ATP in anabolic reactions (DeBerardinis et al., 
2008). Fang and colleagues also proposed an elegant manner by which cancer cells 
promote protein glycosylation in the endoplasmic reticulum, which elevates ATP 
consumption and derepresses the activity of the rate-limiting enzyme PFK (Fang et al., 
2010). Finally, a specific isoform of HK (HKII) that has no allosteric site can be 
overexpressed in cancer cells (Shinohara et al., 1994; Pedersen et al., 2002). 
 
Switching to aerobic glycolysis is the most popular metabolic remodeling described in 
tumor cells. However, bioenergetic studies of the last decade have highlighted that not all 
tumor cells rely on intense glycolysis. Different cancer types and different populations of 
cancer cells inside a given tumor can indeed show variable reliance on glycolysis and 
OXPHOS for ATP production (Jose et al., 2011; Moreno-Sanchez et al., 2014). Metabolic 
activities may indeed be affected by the availability of O2 and nutrients. Some tumor areas 
may be subjected to O2 and/or nutrient deprivation caused by insufficient perfusion (Vaupel 
et al., 1989), thereby leading to cell death or prompting cancer cells to use alternative 
metabolic routes. As an example, preservation of an oxidative metabolism by oxygenated 
tumor cells can be an advantageous manner to spare glucose for glycolytic tumor cells 
(Sonveaux et al., 2008). In the following sections, emphasis on the role of aerobic glycolysis 
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in tumor biology is first given. Then, evidence and importance of functional mitochondrial 
oxidative activity in tumor cells is discussed.  
2. Molecular mechanisms of aerobic glycolysis 
Mutations or epigenetic changes mainly occurring in the phosphatidylinositol 3-kinase 
(PI3K)/Akt/mTOR, hypoxia-inducible factor 1 (HIF-1) and Myc signal transduction systems 
participate in various facets of the Warburg Effect, as reviewed in (DeBerardinis et al., 2008; 
Lunt and Vander Heiden, 2011).  
Metabolic effects of activation of the PI3K/Akt/mTOR pathway include an increased 
uptake of glucose caused by an increased expression of glucose transporters (Wieman et 
al., 2007), and an enhanced glycolytic flux through the modulation of expression and activity 
of glycolytic enzymes (Deprez et al., 1997; Elstrom et al., 2004). Supporting that this 
pathway is a major driver of aerobic glycolysis in cancer cells,  activation of Akt in non-
transformed and tumor cells is sufficient to induce a Warburg Effect (Plas et al., 2001; 
Rathmell et al., 2003). Moreover, mutations that activate PI3K or its effectors constitute the 
most prevalent class of mutations in human tumors (DeBerardinis et al., 2008). 
HIF-1 is a heterodimer composed of HIF-1α and HIF-1β subunits, and the biological 
activity of HIF-1 is determined by the stability of HIF-1α, whose level of expression is 
regulated by O2 levels (Kaelin and Ratcliffe, 2008). Regulation of HIF-1α expression is 
posttranslational: in oxygenated cells, proline hydroxylation promotes HIF-1α association 
with the von Hippel-Lindau (VHL) protein complex, targeting HIF-1α for poly-ubiquitylation 
followed by destruction by the proteasome. Oxygen is a limiting substrate for the proline 
hydroxylation of HIF-1α. Therefore, during hypoxia, HIF-1α escapes proteolytic degradation 
to migrate into the cell nucleus where it binds to HIF-1β. In tumors, constitutive stabilization 
of HIF-1α can occur (Isaacs et al., 2005; Selak et al., 2005; Pollard et al., 2007). This leads 
to the increased expression of glucose transporters and glycolytic enzymes, as well as the 
promotion of pyruvate conversion to lactate (Semenza, 2010).  
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Finally, alterations in the function of oncogenes like Myc (Osthus et al., 2000; Ahuja et 
al., 2010) and Ras (Yun et al., 2009) or of tumor suppressor genes like p53 (Cheung and 
Vousden, 2010) are also described to promote glucose metabolism.  
3. Proliferative advantages  
Energetically speaking, aerobic glycolysis appears as a wasteful version of 
metabolism: incomplete oxidation of glucose to lactate yields only 5 % of the energy 
available from glucose.  However, the persistence of this particular phenotype in primary 
and metastatic cancers, even in conditions of normoxia, indicates that this apparently 
counterproductive behavior can confer a significant advantage to cancer cells. A constitutive 
upregulation of glycolysis indeed makes cancer cells insensitive to transient and permanent 
hypoxic conditions (Granchi et al., 2014). Moreover, enhanced glucose uptake constitutes a 
rapid way to produce ATP for proliferating cells (Pfeiffer et al., 2001). Most importantly, 
glycolysis facilitates rapid cell division as it readily provides metabolic intermediates that can 
be shunted to anabolic pathways, in which they serve as precursors for macromolecules 
(DeBerardinis et al., 2008; Lunt and Vander Heiden, 2011) (figure 2).  
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Figure 2: Glycolysis provides carbon intermediates that fuel the de novo production of lipids, 
nucleotides and amino acids, thereby promoting biomass expansion and cell division. GLUT: 
glucose transporter, HK: hexokinase, PGI: phosphoglucose isomerase, PFK: 
phosphofructokinase, ALDA: aldolase A, TPI: triosephosphate isomerase, GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase, PGK: 3-phosphoglycerate kinase, PGM: 
phosphoglucomutase, ENO: enolase, PK: pyruvate kinase, LDH5: lactate dehydrogenase 5, 
MCT4: monocarboxylate transporter 4, TCA: tricarboxylic acid, PPP: pentose phosphate 
pathway. Adapted from (Payen et al., 2015). 
 
Glycolytic intermediates can fuel several biosynthetic pathways to generate de novo 
nucleotides, lipids and amino acids that are essential for the duplication of the cellular 
biomass during cell division. After its cellular uptake through glucose transporters (GLUTs), 
glucose is phosphorylated by HK, which produces glucose-6-phosphate (G-6-P). G-6-P can 
either continue to proceed into glycolysis, or can be irreversibly shunted to the oxidative 
branch of the pentose phosphate pathway (PPP) by G-6-P dehydrogenase (G6PD) 
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(Hamanaka and Chandel, 2012) (figure 3). The oxidative branch of the PPP is a major 
source of reduced nicotinamide adenine dinucleotide phosphate (NADPH), which protects 
against oxidative stress by electron transfer to thioredoxin/peroxiredoxin and glutathione 
systems, and which also serves as a cofactor necessary for macromolecules biosynthesis 
(Jiang et al., 2014). Lipid synthesis requires a great amount of NADPH, which is readily 
evident when considering the 14 NADPH molecules needed for fatty acyl-CoA generation. 
As each phospholipid is composed of two molecules of fatty acyl-CoA, one can easily figure 
out that cell membrane synthesis require considerable high amount of NADPH 
(DeBerardinis et al., 2008). The reversible non-oxidative branch of the PPP produces the 
nucleotide precursor ribose-5-phosphate (R-5-P), using either the product of the oxidative 
branch (ribulose-5-phosphate) or glycolytic intermediates (Jiang et al., 2014) (figure 3).  
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Figure 3: Using glucose-6-phosphate (glucose-6-P) as a substrate, the oxidative branch of 
the pentose phosphate pathway (PPP) produces NADPH that can be used in biosynthetic 
reactions for lipids and for antioxidant defense. The reversible non-oxidative branch of the 
PPP produces ribose-5-phosphate as well as glycolytic intermediates. G6PD: glucose- 
6-phosphate dehydrogenase, 6PGD: 6-phosphogluconate dehydrogenase, TKT: 
transketolase, Taldo1: transaldolase 1, HK: hexokinase, GLUT: glucose transporter, PFK1: 
phosphofructokinase-1, PGM: phosphoglyceratemutase, PKM2: pyruvate kinase M2, LDHA: 
lactate dehydrogenase A, FBP: fructose-1,6-bisphosphate, PEP: phosphoenolpyruvate. 
Jiang et al., 2014. 
 
Coming back to glycolysis, dihydroxyacetone-phosphate, a metabolic intermediate 
coming from the cleavage of fructose-1,6-bisphosphate, is the precursor of glycerol-3-
phosphate, which is crucial for the biosynthesis of the phospholipids and triacylglycerols that 
serve as major structural lipids in cell membranes (Lunt and Vander Heiden, 2011). 
Glyceraldehyde-3-phosphate and fructose-6-phosphate can combine to generate R-5-P, 
thereby contributing to nucleotide synthesis. Finally, protein synthesis can also be supported 
 
                                                                                                                                                        Introduction                                    
                                                                                                                                                 
19 
 
by a high rate of glycolysis as the carbons of four amino acids are derived from two 
glycolytic intermediates: 3-phosphoglycerate, which provides carbons for cysteine, glycine 
and serine, and pyruvate, which provides carbons for alanine (DeBerardinis et al., 2008; 
Hamanaka and Chandel, 2012). 
In proliferating cells, carbons from pyruvate that enter the mitochondrial TCA cycle can 
also be diverted to biosynthetic pathways through the process of cataplerosis, therefore 
further participating to macromolecules synthesis. The role of mitochondria in redirecting 
energy-containing intermediates from ATP production towards biosynthesis is discussed in 
section III.2. 
4. Consequences on the tumor microenvironment  
Highly glycolytic cancer cells produce large amounts of lactate and protons that must 
be exported to avoid an intracellular acidification that would otherwise lead to cell death 
(Dhup et al., 2012). Moreover, intracellular pH (pHi) must be kept in a narrow range, 
otherwise cell cycle progression and biosynthetic processes could be compromised 
(Madshus, 1988). This can be achieved by monocarboxylate transporters (MCTs) that 
couple the export of each molecule of lactate with a proton (Dimmer et al., 2000). Other 
important systems that catalyze proton exports include carbonic anhydrases (CAs), 
membrane-bound vacuolar ATPase (V-ATPase) and the sodium proton exchanger (NHE1) 
(Dhup et al., 2012). CO2 generated from various sources also contributes to tumor 
acidification (Dhup et al., 2012). Indeed, through the action of CAIX, secreted CO2 can be 
hydrated into bicarbonate (HCO3
-) and H+ (Parks et al., 2011).  
In cancer cells, all these systems result in a transmembrane gradient of protons 
opposite to that in normal cells; with a neutral or slightly alkaline intracellular pH (pHi ≥ 7.4) 
and an acidic extracellular pH (pHe = 6.5-6.9) (Gillies et al., 1994). As reviewed in (Gatenby 
et al., 2006; Dhup et al., 2012; Estrella et al., 2013) acidification has important role in tumor 
progression as it promotes invasiveness by reducing the proliferation and viability of 
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surrounding stromal cells, induces the breakdown of the extracellular matrix, promotes 
angiogenesis, and decreases immune responses to tumor antigens. Therefore, 
overexpression of the pH-regulating systems mentioned above is usually associated with 
poor prognosis (Sennoune et al., 2004; Hussain et al., 2007; Chiang et al., 2008). 
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II. Targeting aerobic glycolysis 
 
With the deepened understanding that enhanced glycolysis is a common feature of cancer 
cells and a key contributor to tumor growth and invasion, different approaches to tackle this 
Achilles’ heel have been explored. Many compounds have been developed to selectively 
inhibit aerobic glycolysis in several tumor models (Granchi et al., 2014).  A recent update of 
drugs currently in clinical trials is available in Table 1.  
The major concern associated with targeting cancer cell metabolism lies on the fact that all 
cells use the same metabolic network; and the disruption of any of these metabolic 
processes has the potential to affect both cancer and normal cells. Moreover, the majority of 
metabolic enzymes are not mutated (Elf and Chen, 2014). Combination of drugs is therefore 
increasingly considered as an important avenue to be explored in order to reduce drug 
doses and spare normal cell. Moreover, dysregulated metabolism directly affects 
chemosensitivity via multiple pathways (Zhao et al., 2013). The most significant advances 
and remaining challenges concerning (1) reduction of glucose entry into the cell, (2) 
inhibition of glycolytic enzymes or (3) redirection of pyruvate from lactate production are 
discussed below. 
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Table 1: Update of clinical studies targeting glucose metabolism for cancer therapy. 
  From Granja et al., 2015. 
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1. Reduction of glucose entry into the cell 
Due to the fundamental role of glucose uptake in the glycolytic pathway, targeting 
glucose transporters (GLUTS) is an attractive approach to inhibit tumor growth. Different 
GLUT isoforms (GLUT1, GLUT3 and GLUT4) have been found to be overexpressed in a 
wide variety of cancers (Szablewski, 2013) and their level of expression often correlates to 
bad prognosis (Adekola et al., 2012). Silybin/silibinin is a natural compound that was 
recently shown to be a GLUT inhibitor (Zhan et al., 2011). Pre-clinical in vitro and in vivo 
studies showing encouraging results (Deep and Agarwal, 2010) led to phase I and II clinical 
trials in patients with prostate cancer (NCT00487721) and advanced hepatocellular 
carcinoma (NCT01129570). No relevant anticancer effects were obtained because of a poor 
drug penetration in cancer tissues, which was accompanied by acute toxicity. However, as it 
was recently shown that silybin can reverse drug resistance and increase chemotherapeutic 
drug efficacy (Cufi et al., 2013; Hussain and Marouf, 2013; Sadava and Kane, 2013), a 
phase II clinical trial was recently launched that will assess the efficacy of combined erlotinib 
with silybin (NCT02146118). Other natural (phloretin, (+)-cryptocaryone, methylxanthin) or 
synthetic (WZB117, STF-31, oxime derivatives) compounds inhibiting glucose transporters 
have shown promising pre-clinical results too, but the question of selectivity remains a major 
concern (Granchi et al., 2014; Granja et al., 2015). The potential toxicity associated with 
glucose deprivation in healthy tissues that primarily depend on glucose metabolism (such as 
the brain) is indeed a major challenge for their use in vivo. The crystal structure of human 
GLUT1 was very recently obtained (Deng et al., 2014), which will most probably help to 
develop new selective inhibitors. 
2. Inhibition of glycolytic enzymes 
Owing to the fact that they catalyze reactions essentially irreversible, efforts have 
mainly focused on the specific inhibition of HK, PFK and PK, the three rate-limiting enzymes 
of glycolysis. Although less characterized or still under development, compounds targeting 
 
Introduction 
24 
 
other enzymes in glycolysis, such as phosphoglycerate mutase (PGM) and enolase (ENO), 
are also under investigation (Granchi et al., 2014).  
2.1 Hexokinase 
HK is the first rate-limiting enzyme of the glycolytic pathway that phosphorylates 
glucose to yield G-6-P, trapping glucose inside the cell (figure 2). The glucose analogue 2-
deoxy-D-glucose (2-DG) is the most widely used and advanced clinical agent inhibiting 
cancer metabolism (El Mjiyad et al., 2011). 2-DG is phosphorylated by HK to generate 2-
DG-6-P but it cannot be further metabolized, therefore inhibiting HK activity non-
competitively. Although 2-DG is mainly described as a HK inhibitor, 2-DG-6-P also acts as a 
competitive inhibitor of enzymatic reactions that use G-6-P as a substrate, therefore 
inhibiting both glycolysis and the PPP. 2-DG may also compete with glucose for GLUT 
transporters, therefore decreasing glucose uptake by the cell (Granja et al., 2015). The 
anticancer effects of 2-DG include inhibition of proliferation and colony formation in vitro, as 
well as in vivo tumor growth inhibition (Laszlo et al., 1960; Kern and Norton, 1987; Bell et al., 
1998). Moreover, induction of apoptosis, autophagy, proteolytic events and endoplasmic 
reticulum stress were also reported (Kuntz et al., 2014). Upon determining the clinically 
tolerable dose, a completed phase I clinical trial reported significant adverse effects 
associated to 2-DG delivery (63-88 mg/kg), such as hyperglycemia, gastrointestinal bleeding 
and cardiac abnormalities (NCT00096707). It was realized that to achieve therapeutic 
effects, high doses of 2-DG would be required. In view of the risk of toxicity, other trials 
(NCT00247403 and NCT00633087) that aimed to treat cancer with 2-DG were discontinued. 
In vitro studies using a combination of 2-DG with standard therapeutic agents such as 
cisplatin and docetaxel showed that 2-DG may potentiate the effect of standard therapy 
(Maschek et al., 2004; Ciavardelli et al., 2014). 2-DG also sensitized gliomas and other cell 
lines to ionizing radiations without inducing relevant side effects (Khaitan et al., 2006; 
Sharma et al., 2012). 
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The HK family comprises 4 isoforms, with isoform II (HKII) predominantly 
overexpressed in malignant lesions (Shinohara et al., 1994; Pedersen et al., 2002). HKII has 
the particularity to be located at the outer membrane of mitochondria, where it interacts with 
the voltage dependent anion channel (VDAC). Upregulation of this mitochondria-bound 
isoform offers a preferential access of HK to newly synthesized ATP for glucose 
phosphorylation, and contributes to inhibition of apoptosis through blocking of cytochrome C 
release via VDAC (Mathupala et al., 2009). Importantly, most normal mammalian tissues 
express very little HKII which suggests that only limited side-effects are expected from 
compounds selectively targeting HKII (Vander Heiden, 2011). Lonidamine is a synthetic 
compound described as a specific inhibitor of mitochondrial-bound HK (Floridi et al., 1981) 
that has shown promising anticancer effects in various tumor types (reviewed in (Di Cosimo 
et al., 2003)). Until recently, lonidamine was in phase II/III clinical studies for the treatment of 
patients with prostate cancer (NCT0435448 and NCT00237536); however, the trials have 
been suspended due to liver toxicity. An inhibitory activity on HKII was also demonstrated for 
anticancer agents with multiple mechanisms of action, such as 3-bromo-pyruvate 
(Mathupala et al., 2009) and metformin (Salani et al., 2013). Besides this, a pharmaceutical 
company (vTvtherapeutics) and scientists of the Okinawa Institute of Science And 
Technology (Cui and Tanaka, 2013) are currently developing and studying the effects of 
novel specific HKII inhibitors, which could lead to interesting results in the near future.  
2.2 Phosphofructokinase 
PFK-1 catalyzes one of the most critical steps of glycolysis, the conversion of 
fructose-6-phosphate and ATP to fructose-1,6-bisphosphate and ADP (figure 2). The activity 
of PFK-1 is highly regulated, with fructose-2,6-bisphosphate acting as a powerful allosteric 
activator. As the main provider of fructose-2,6-bisphosphate, PFKFB3 (a member of the 
PFK-2 family) is an important contributor to the high glycolytic activity of cancer cells (Ros 
and Schulze, 2013). Its activity can be reduced with the selective inhibitor 3PO (3-(3-
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pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) (Clem et al., 2008). 3PO was reported to decrease 
the concentration of fructose-2,6-bisphosphate, leading to decreased glucose uptake and to 
cancer growth suppression in vitro and in vivo (Clem et al., 2008). Very recently, further 
optimization of this small molecule led to the synthesis of PFK158, a more potent inhibitor of 
PFKFB3 for testing in the clinics. The phase I clinical trial has started in March 2014 and is 
presently recruiting participants (NCT02044861). 
2.3 Pyruvate kinase  
PK catalyzes the final rate-limiting step of glycolysis, which consists in the transfer 
of a phosphate group from phosphoenolpyruvate (PEP) to ADP, to yield pyruvate and ATP 
(figure 2). The M1 isoform is expressed in normal proliferating cells, whereas the M2 isoform 
is expressed during embryonic development and in many cancers (Christofk et al., 2008). 
PKM2 is the only PK to be allosterically regulated between a less active dimer and an active 
tetramer (Wong et al., 2013). These different forms of PKM2 regulate glucose metabolism 
through either the TCA cycle or glycolysis. The dynamic equilibrium between dimer and 
tetramer PKM2 allows proliferating cells to regulate their needs for anabolic and catabolic 
metabolism. In 2007, Thallion Pharmaceuticals launched the first clinical trial (phase II) with 
the PKM2 inhibitor TLN-232 (NCT00422786) in patients with refractory metastatic renal cell 
carcinoma. The drug was generally safe and well tolerated, with 2 out of 3 patients that 
completed the study with a stable disease (Granja et al., 2015). A second phase II clinical 
trial for the treatment of metastatic melanoma patients was suspended in 2010 for legal 
reasons (NCT00735332). Approaches that enhance PKM2 activity to promote OXPHOS 
have also been considered. In preclinical studies, PKM2 activators showed inhibitory effects 
on cancer cells proliferation and tumorigenesis (Anastasiou et al., 2012).  
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3. Redirecting the fate of pyruvate from lactate production toward 
mitochondrial oxidation 
3.1 Lactate dehydrogenase 
LDHs belong to a family of tetrameric enzymes that are formed by two different 
subunits, M and H, assembled to form active tetramers. Five distinct enzymes, LDH1 to 
LDH5, therefore exist (Porporato et al., 2011). LDH1 is ubiquitously expressed in normal 
tissues and preferentially catalyzes the reduction of lactate to pyruvate. Conversely, LDH5 is 
highly expressed in many human tumors and preferentially catalyzes the opposite reaction; 
oxidizing pyruvate to lactate (figure 2) (Koukourakis et al., 2009). LDH5 also allows to 
maintain a high rate glycolytic flux by generating NAD+, a cofactor required for the reaction 
catalyzed by the glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The antimalarial 
natural compound gossypol (AT101) competes with NADH and inhibits LDH5 with a low Ki 
(1.9 µM) (Granja et al., 2015). Unfortunately, clinical studies using AT101 in monotherapy 
(NCT00773955) or in combination with chemotherapy (NCT00397293) revealed 
disappointing results or were interrupted. New studies with AT101 in combination with other 
drugs are starting to recruit patients (NCT01003769 and NCT01977209). FX11, a gossypol-
derived compound has shown interesting anti-proliferative properties in vitro and in vivo (Le 
et al., 2010). No clinical evaluation of FX11 has been initiated yet, but it would maybe 
provide new opportunities to target LDH5, although significant toxicity and off-target effects 
are expected (Granchi et al., 2014).  
3.2 Pyruvate dehydrogenase kinase  
PDK is a mitochondrial kinase that negatively regulates the activity of pyruvate 
dehydrogenase (PDH), the enzymatic complex responsible for the irreversible conversion of 
pyruvate to acetyl-CoA (Holness and Sugden, 2003) (figure 4). By phosphorylating PDH, 
PDK effectively blocks PDH activity, thus preventing pyruvate entry into the TCA cycle and 
forcing the cells to switch to glycolysis for energy production.                                   
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PDK is reversibly regulated by the products (acetyl-CoA and NADH) and substrate 
(pyruvate) of the PDH reaction (Bowker-Kinley et al., 1998). There are four human isomeric 
forms of PDK (PDK1-4), with tissue-specific expression and singular activities (Patel et al., 
2014). PDK1 (Kim et al., 2006; Papandreou et al., 2006; McFate et al., 2008; Kaplon et al., 
2013) and PDK3 (Lu et al., 2008) are known to be target gene products of HIF-1 and have 
been found expressed in cancer cells. PDK2 is also expressed in many tumors (Bonnet et 
al., 2007; Michelakis et al., 2010) and has been found to be repressed by the tumor 
suppressor gene p53 (Contractor and Harris, 2012). PDK4 can be activated by the 
oncogenic Rb/E2F1 pathway, suggesting a role of PDK4 in tumor biology (Hsieh et al., 
2008).  
3.2.1 Targeting PDK with dichloroacetate 
Because of their strategic location, PDKs have already been considered as 
important therapeutic targets. Dichloroacetate (DCA) was identified as a PDH activator 40 
years ago (Whitehouse and Randle, 1973). It is now known that this pyruvate mimetic acts 
Figure 4: 
The intramitochondrial pyruvate 
dehydrogenase kinase (PDK) 
inhibits pyruvate dehydrogenase 
(PDH) activity through 
phosphorylation, thereby inhibiting  
the metabolization of pyruvate in 
mitochondria. 
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by inhibiting the action of the PDKs. The crystal structure of PDK2 bound to DCA has been 
obtained, and it appears that DCA occupies the pyruvate-binding site in the N-terminal 
regulatory domain (Knoechel et al., 2006). The four isozymes vary considerably in their 
sensitivity to inhibition by DCA. PDK2 is the most sensitive, PDK3 the most resistant, 
whereas the sensitivities of PDK1 and PDK4 are intermediate (Bowker-Kinley et al., 1998).  
3.2.2 Dichloroacetate as an anticancer treatment 
DCA has already been used in humans as a treatment for congenital lactic 
acidosis (Stacpoole et al., 1992). In these patients, pyruvate cannot be oxidized in the 
mitochondria because of a lack or a decreased expression of mitochondrial enzymes, and 
pyruvate is metabolized to lactate by LDH. In 2007, Bonnet and coworkers (Bonnet et al., 
2007) first reported the anticancer properties of DCA. They showed that DCA changes the 
metabolism of cancer cells from cytoplasm-based glycolysis to mitochondria-based 
oxidation. This was associated with an increased production of reactive oxygen species 
(ROS), decreased mitochondrial membrane potential, decreased efflux of proapoptotic 
mediators from mitochondria (cytochrome C and apoptosis-inducing factor [AIF]), and 
induction of apoptosis. In vivo, daily oral administration of DCA reduced tumor growth. The 
authors also showed that cancer cells are more sensitive to DCA treatment because they 
exhibit hyperpolarized mitochondria, which is thought to confer resistance to apoptosis.  
Based on the results of this initial study by Bonnet et al; DCA has quickly been 
evaluated as a potent anticancer drug in the clinics. Indeed, its structure (a very small 
molecule able to cross the blood-brain barrier), its low price (it is a generic drug) and the fact 
that DCA has already been used in humans provided a strong rationale for rapid clinical 
evaluation (Michelakis et al., 2008). In 2010, outcomes of the first clinical trial in five patients 
with glioblastoma were available (NCT00540176). DCA treatment was associated with a 
prolonged stabilization or tumor regression and, in general, displayed an overall good safety 
profile. Dose-limiting toxicity was a peripheral neuropathy that was reversible upon DCA 
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dose reduction (Michelakis et al., 2010). Another phase I trial (NCT01111097) in patients 
with glioblastoma or recurrent brain tumor (completed in 2014) showed that oral DCA 
administration is safe, well-tolerated and feasible. In this trial, dosing was based on 
haplotype variation in glutathione transferase zeta 1 (GSTZ1), which participates in DCA 
catabolism. Consequently, no dose-limiting toxicity occurred. No patient withdrew because 
of lack of tolerance to DCA. Importantly, DCA therapy was associated with clinical and 
radiographic evidence of disease stabilization in eight out of fifteen patients (Dunbar et al., 
2014). Conversely, a phase II trial conducted in patients with refractory metastatic breast 
and non-small cell lung cancers (NCT01029925) was prematurely terminated based on 
higher than expected risk and safety concerns. To date, two other clinical studies using DCA 
in monotherapy are ongoing and could provide more information about the clinical use of 
DCA in cancer therapy (NCT00566410 and NCT01163487). One trial using oral DCA in 
combination with cisplatin and radiation treatment in patients with head and neck carcinoma 
is ongoing (NCT01386632). 
3.2.3 Other mechanisms attributed to dichloroacetate 
Since the initial work by Bonnet et al., DCA has been widely studied alone or in 
combination with other treatments, as reviewed in (Kankotia and Stacpoole, 2014). From 
these in vitro and in vivo studies, it was generally concluded that induction of ROS-mediated 
apoptosis is the main mechanism accounting for the tumoricidal action of DCA. 
Nevertheless, some groups recently reported distinct mechanisms, and this hypothesis has 
been questioned. Using a panel of sixteen cancer and normal cell lines, a systematic study 
of Stockwin and coworkers (Stockwin et al., 2010) highlighted that DCA is relatively inactive, 
inducing apoptosis only at high concentrations (≥ 25 mM, 48 h). At lower concentrations, 
DCA depolarizes mitochondria, increases ROS generation and inhibits cell growth without 
apoptosis induction. Interestingly, increased ROS levels were not implicated in the anti-
proliferative effects of DCA. It was rather suggested that, at clinically relevant doses, DCA is 
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a metabolic modulator that negatively impacts cell growth without apoptosis induction. 
Another study, that used hypoxic HeLa cervical and PANC-1 pancreatic cancer cells to 
evaluate the in vitro effects of DCA reported that 94 % of the cells were viable at doses of 
12.5 mM (24 h treatment) (Anderson et al., 2009). In HT29 and LoVo cell lines isolated from 
colorectal adenocarcinomas, there were increases of 2.8 % and 21 % in total apoptotic cells 
following 50 mM of DCA treatment for 48 h, respectively (Madhok et al., 2010). Similarly, in 
two other recent studies, an apoptotic response was triggered at concentrations of DCA that 
were too high to be clinically relevant (Abildgaard et al., 2014; Delaney et al., 2015). Taken 
together, these reports show that DCA can have different actions that may likely depend on 
drug concentration and cell type. 
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III. Targeting mitochondria 
 
Oxidative metabolism and TCA cycle functions in cancer cells have been the subject of 
intense debate. This is in part due to Warburg’s hypothesis claiming that the origin of cancer 
was a permanent, irreversible impairment of OXPHOS (Warburg, 1956). However, metabolic 
flux experiments tracking carbon-labeled nutrients have shown that the TCA cycle remains 
intact in cancer cells exhibiting a pronounced Warburg phenotype (DeBerardinis et al., 
2007). In addition, a significant population of cancer cells may predominantly rely on 
OXPHOS for ATP production (Zu and Guppy, 2004; Moreno-Sanchez et al., 2014). 
Therefore, increasing evidence indicates that mitochondrial activity is not fundamentally 
impaired, but rather actively participates in the transformation process by maintaining the 
biosynthetic capacity of cancer cells. As discussed below, several strategies consisting in 
inhibiting mitochondria alone or in combination with cytotoxic modalities such as 
radiotherapy have already been evidenced to constitute appealing approaches for cancer 
therapy.  
1. Electron transport chain and oxidative phosphorylation  
The initial statement made by Warburg on the origin of cancer was immediately 
criticized with the demonstration by Sidney Weinhouse that the mitochondrial function in 
cancer tissues was most often normal and that information supporting Warburg’s hypothesis 
was affected by misinterpretation (Weinhouse, 1956). In fact, analysis of the degree of 
inhibition of glycolysis by metabolic intermediates including ATP derived from OXPHOS (the 
“Pasteur Effect”) showed that aerobiosis can reduce glycolysis in most cancer cells, 
indicating a normal oxidative capacity in tumors (Weinhouse, 1976). More recent 
experimental studies have also provided evidence that mitochondrial activity is not 
fundamentally impaired in many cancer cells: 
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- Diverting pyruvate into the mitochondria through inhibition of LDH (Fantin et al., 2006) 
or activation of PDH by targeting its inhibitor PDK with DCA (Bonnet et al., 2007) can 
significantly induce respiration in cancer cells. 
- Under glucose starvation, most cancer cells can survive when making ATP exclusively 
by OXPHOS (Rossignol et al., 2004)  
- Despite enhanced rates of glycolysis, Zu and Guppy (Zu and Guppy, 2004) showed 
that OXPHOS was the main ATP supplier in an extensive number of cancer cell lines. 
- A point that is often overlooked is that re-oxidation by the ETC of NADH formed by 
TCA cycle enzymes or by glycolysis in the cytosol is required for the continuous supply 
of citrate, the only source for the synthesis of cytosolic lipogenic precursor acetyl-CoA 
(see III.2 for more details) (Moreno-Sanchez et al., 2014). 
 
Overall, there are still some examples of tumor cell lines that exhibit decreased 
mitochondrial functions caused by mutations in either mitochondrial-encoded or in nuclear-
encoded mitochondrial proteins (Carew and Huang, 2002; Chatterjee et al., 2006; Frezza et 
al., 2011). As examples, the TCA cycle enzymes isocitrate dehydrogenase (IDH), succinate 
dehydrogenase (SDH) and fumarate hydratase (FH) have been found deleted or mutated in 
various forms of cancer. Mutations affecting respiratory chain complexes have also been 
reported. But growing evidence suggests that most cancer cells are capable of performing 
OXPHOS. As was hypothesized by Frezza and Gottlieb (Frezza and Gottlieb, 2009), 
decreased OXPHOS could in many cases rather be a consequence of accelerated 
glycolysis and an increased use of pyruvate for lactate production driven by genetic and/or 
environmental alterations. A suggested hypothesis is that sustained respiration inhibition by 
glycolysis is caused by glycolysis competing with oxidative OXPHOS for inorganic 
phosphate (Pi) and ADP.  
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Preclinical and clinical evaluation of several compounds targeting mitochondrial 
respiration has shown encouraging results. Resveratrol is a natural compound found in 
grapes that binds to ATP synthase and inhibits ATP synthesis. Research using cancer cells 
has shown promising and positive effects of resveratrol implicating different mechanisms. 
However, evidence from rodents and humans is inconsistent (Patel et al., 2010; Carter et al., 
2014). Retrospective clinical and laboratory evidence further strongly suggests that the 
antidiabetic drug metformin acts as an anticancer agent (Evans et al., 2005; Dowling et al., 
2012). The tumoricidal effects of metformin are not entirely clear, but studies demonstrated 
that metformin when used in vitro inhibits mitochondrial complex I (El-Mir et al., 2000; Owen 
et al., 2000) and in vivo models have shown that the antitumor effects of metformin are 
dependent on its ability to inhibit this complex (Fendt et al., 2013; Wheaton et al., 2014). 
Other reports using mitochondrial inhibitors that selectively target ATP transport or OXPHOS 
processes can be found in these reviews (Ramsay et al., 2011; Wen et al., 2013; Weinberg 
and Chandel, 2015). For the moment, only few molecules progressed beyond preclinical 
investigations. 
2. TCA cycle 
In non-proliferating cells, a main role of the TCA cycle is to fuel ATP production. In 
proliferating cells such as cancer cells in growing tumor areas, however, the TCA cycle 
serves as an important source of biosynthetic precursors in addition to providing ATP 
(DeBerardinis et al., 2008; Frezza and Gottlieb, 2009) (figure 5): 
- TCA cycle-derived citrate is the only source for the synthesis of cytosolic acetyl-CoA 
required for lipid synthesis.  
- Oxaloacetate (OAA) and α-ketoglutarate supply intracellular pools of non-essential 
amino acids (aspartate, asparagine, glutamate, proline, arginine) used for the 
production of proteins and nucleotides  
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- Malate, once exported from mitochondria, serves to produce NADPH and pyruvate, a 
precursor of alanine. 
 
In order to sustain TCA cycle functions and face cataplerosis (depletion of TCA cycle 
intermediates supporting biosynthesis), cells must have a matching influx of intermediates 
that replenish the cycle (anaplerosis). An important source of anaplerosis is the metabolism 
of glutamine, the most abundant amino acid in mammals (DeBerardinis et al., 2007). In the 
cytosol, glutamine donates nitrogen to purines and pyrimidines, resulting in the formation of 
glutamate. Glutamate produces non-essential amino acids and α-ketoglutarate, which can 
replenish the TCA cycle in carbon intermediates. In addition, cells can partially oxidize α-
ketoglutarate derived from glutamine (Reitzer et al., 1979), which increases the cytosolic 
production of NADPH and pyruvate, a precursor of alanine. 
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Figure 5: Proliferating cells such as cancer cells can use TCA cycle intermediates as 
precursors for biosynthesis. Glucose and glutamine are two important carbon sources that 
fuel the TCA cycle. They are converted into citrate that is exported to the cytosol to 
participate in the synthesis of fatty acids and cholesterol. Oxaloacetate and α-ketoglutarate 
are also used to generate non-essential amino acids. α-ketoglutarate derived from glutamine 
is ultimately sequentially converted to malate, pyruvate and lactate, generating additional 
NADPH (the malic enzyme reaction), NAD+ and lactate (the lactate dehydrogenase 
reaction). Adapted from Vander Heiden and Lunt., 2011. 
 
Although anaplerosis can be achieved by pyruvate and glutamine, increasing evidence 
suggests that glutamine may predominate over the use of pyruvate in many cancer cells 
(Medina et al., 1988; Souba, 1993; DeBerardinis et al., 2007). On the other hand, using 
stable isotope labeling coupled with nuclear magnetic resonance analysis, a group showed 
that orthotopically implanted human glioblastoma cells preferentially use glucose – rather 
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than glutamine – to produce TCA cycle intermediates (Marin-Valencia et al., 2012). 
Undoubtedly, metabolic constraints imposed by the in vivo environment profoundly influence 
the way cancer cells metabolize substrates. Nevertheless, targeting glutamine metabolism 
has already shown therapeutic potential in preclinical studies. For example, 
aminooxyacetate (AOA) is a global inhibitor of transaminases that are involved in amino acid 
metabolism. It was reported to deplete both aspartate and alanine, decrease proliferation of 
cancer cells, and suppress tumor growth in mice (Thornburg et al., 2008; Wise et al., 2008; 
Korangath et al., 2015). Glutamine analogs have also been explored as possible therapies 
for cancer. The antitumor effect of these compounds is believed to be exerted by inhibiting 
glutamine-dependent biosynthesis.  Development of acivicin, 6-diazo-5-oxo-L-norleucine, 
and azaserine, three of the most widely studied glutamine analogs, has however been 
halted because of lack of tumor specificity and significant side-effects such as neurotoxicity, 
gastrointestinal toxicity and myelosuppression (Wise and Thompson, 2010; Hensley et al., 
2013). A more selective approach could be obtained by targeting SLC1A5, the transporter 
implicated in glutamine uptake by cancer cells. It has been shown that γ-L-glutamyl-p-
nitroanilide (GPNA) inhibits this transporter and limits lung cancer cell growth (Hassanein et 
al., 2013). 
3. Sensitization to radiotherapy 
Radiation therapy (RT) plays an important role in the care of patients with cancer. For 
example, approximately 75% of patients with head and neck cancer do benefit from RT as 
part of their treatment (Barton et al., 2014). However, RT efficacy is severely compromised 
by hypoxia, a common feature of solid tumors. In the following section, we will discuss the 
influence of hypoxia on the radioresponse of tumors. The radiosensitizing approach that 
consists in increasing tumor oxygenation by inducing a decrease in mitochondrial O2 
consumption will be emphasized.  
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3.1 Effect of tumor hypoxia on the radioresponse of tumors 
Hypoxia results from an imbalance between O2 supply and consumption within a 
tissue. In solid tumors, structural and functional vascular abnormalities lead to insufficient O2 
supply to cells with high metabolic activities. Accordingly, O2 partial pressure (pO2) values of 
2.5 mmHg or less are characteristic of advanced solid tumors in a wide range of human 
cancers (Tatum et al., 2006).  
It has been recognized for approximately 60 years that hypoxia profoundly 
decreases RT efficacy and is associated with poor clinical outcome. O2 tensions below 10 
mmHg are estimated to significantly reduce radiosensitivity (Thomlinson and Gray, 1955). It 
is related to the fact that O2 generates superoxide and fixes DNA damage following radiation 
treatment (Jordan and Sonveaux, 2012) (figure 6). Therefore, strategies that increase the 
delivery and/or decrease the metabolic utilization of O2 can potentially render tumors more 
sensitive to radiation. 
 
 
 
Figure 6: Oxygen potentiates RT efficacy. Oxygen is required for the generation of 
superoxide following water radiolysis. It is also important to stabilize ROS-generated DNA 
peroxides,i.e., stable DNA lesions that cannot be easily repaired. Jordan and Sonveaux, 
2012. 
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Most attempts to reduce tumor hypoxia have focused on increasing the O2 supply. 
However, these trials have met limited success. Indeed, combination of RT with approaches 
consisting in breathing O2-enriched gases showed limited clinical impact (Higgins et al., 
2015). Nimorazole, which acts as an O2 mimetic, showed decreased locoregional recurrence 
rates but failed to improve the survival of patients with head and neck cancer (Overgaard et 
al., 1998); so that these findings have had no impact on general clinical practice except for 
Denmark. Studies on strategies that improve tumor oxygenation by achieving vasodilatation 
(the “provascular” approach) have provided encouraging data. However, it is important to 
note that because the proportion of mature vasoactive blood vessels is limited in solid 
tumors, vasodilators must be tumor-selective in order to increase tumor perfusion. 
Nonselective vasodilation would rather decrease tumor perfusion and oxygenation because 
blood would ooze out of the tumor to the normal tissues with lower vascular resistance to 
flow (“Steal Effect”) (Danhier et al., 2013).  
3.2   Reducing the oxygen demand to improve radiosensitivity 
An alternative approach to increasing O2 delivery to tumors to reduce tumor 
hypoxia is to decrease the O2 demand by mitochondria, which account for most of cellular 
O2 consumption. It has not yet attracted great interest in clinical trials but several arguments 
concur to indicate that targeting mitochondrial metabolism appears to be a good strategy to 
radiosensitize tumors:  
- It is now recognized that most cancer cells have active OXPHOS, even if this 
activity is limited in highly glycolytic cells. 
- Experimental evidence indicates that respiratory complex IV (cytochrome C 
oxidase) Km value for O2 is in the range of 1 µM, thus ETC is able to function 
optimally at pO2 values between 2.5 - 10 mmHg (equivalent to 3-13 µM O2) 
(Scandurra and Gnaiger, 2010). Consequently, mitochondrial inhibitors may allow 
sparing O2 even in hypoxic tumor regions.  
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- It has been mathematically demonstrated (Secomb et al., 1995) and experimentally 
validated (Diepart et al., 2012) that targeting O2 consumption is a very effective 
way to reduce tumor hypoxia. 
 
Several pharmacological drugs that inhibit O2 consumption have been 
characterized preclinically for their potential to increase tumor oxygenation and enhance the 
radiosensitivity of tumors (reviewed in (Jordan and Sonveaux, 2012)). A recent paper further 
showed that metformin can reduce the O2 consumption rate and radiosensitize cancer cells 
by blocking complex I activity in the ETC. Metformin reduced tumor hypoxia in xenograft 
models without altering blood flow, and caused marked tumor regrowth delay following 
irradiation (Zannella et al., 2013). Metformin combined with radiotherapy is likely to be well 
tolerated, since numerous diabetic patients with cancer have already received these 
treatments concurrently without any reported safety concerns (Higgins et al., 2015). 
3.3   Nitric oxide: a small molecule with multiple radiosensitizing mechanisms 
Nitric oxide (NO) is an endogenous gas, the use of which represents a feasible and 
safe therapeutic option for radiotherapy. Treatments acting either by exogenous 
administration of NO donors or by the stimulation of endogenous production revealed that 
NO can radiosensitize tumors by at least 3 mechanisms:  
- Vasodilation: Systemic administration of exogenous NO with isosorbide dinitrate, 
xanthinol nicotinate or S-nitrosocaptopril resulted in an improvement of 
oxygenation in experimental tumors due to an increase in tumor blood flow (Jordan 
et al., 2000; Jordan et al., 2010; Segers et al., 2010). In the same line, electrical 
stimulation of endogenous NO synthesis also increased tumor blood flow and pO2. 
This was attributed to the fact that NO acts as a major endothelium-derived 
relaxing factor (EDRF) (Palmer et al., 1987). All treatments were efficient at 
radiosensitizing tumors.  
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- Inhibition of oxygen consumption: Some of the treatments cited above 
concomitantly decreased the rate of O2 consumption by tumor cells. Indeed, NO 
also reversibly inhibits complex IV (Brown and Cooper, 1994). Inhibition of tumor 
cell O2 consumption has also been described in the context of insulin-induced NO-
dependent enhanced radiosensitivity (Jordan et al., 2002).   
- RT damages stabilization: The mismatch between the amplitude of the tumor 
reoxygenation and the radiotherapeutic response in vivo suggested that NO also 
possesses intrinsic radiosensitizing properties (Jordan et al., 2004). Hence, it has 
been proposed that NO acts as an intrinsic radiosensitizer because of its radical 
nature and its direct participation to the stabilization of DNA damage (Mitchell et 
al., 1993; Griffin et al., 1996). 
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IV. Hydrogen sulfide 
1. Endogenous production in mammals 
Until recently, H2S was seen almost exclusively as a toxic gas devoid of physiological 
significance. After carbon monoxide (CO) and nitric oxide (NO), H2S is now considered the 
third member of the gaseous transmitter family in mammals (Wang, 2002) (figure 7).  
 
     
 
Figure 7: General characteristics of nitric oxide (NO), carbon monoxide (CO) and 
hydrogen sulfide (H2S), the three recognized gasotransmitters in mammals. (Polhemus and 
Lefer, 2014). 
 
H2S is a small gaseous molecule that is freely permeable to membranes. It is 
enzymatically generated in the body, and its endogenous metabolism is regulated. Among 
the enzymes involved in the endogenous production of H2S, CBS (cystathionine-β-synthase) 
and CSE (cystathionine-γ-lyase) account for the major portion of H2S. These enzymes use 
amino acids L-cysteine, L-homocysteine and L-cystathionine to produce H2S with pyridoxal 
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5’-phosphate (vitamin B6) as a cofactor (Wang, 2012). In addition, a minor endogenous 
source of H2S is the non-enzymatic reduction of elemental sulfur to H2S (Wang, 2012). The 
physiological concentrations of H2S range from high nM up to about 100 µM in the blood 
circulation of animals and humans (Richardson et al., 2000; Hyspler et al., 2002). 
2. Interactions with mitochondria 
An important characteristic of H2S is that, under certain circumstances, it may induce 
opposite biological responses. Mitochondria are important targets of H2S and interactions 
are complex. Indeed, H2S produces biphasic effects on cell respiration; inhibiting it at 10 µM 
and above but stimulating it at lower concentrations. The following section will describe how 
H2S can act as an inhibitor or a stimulator of the ETC.  
2.1. Inhibitory effects of H2S on mitochondrial respiration 
Similar to NO and CO, the primary molecular target of H2S is the mitochondrial 
complex IV (Petersen, 1977). Using a synthetic model of cytochrome C oxidase (Cox), 
Collman and colleagues (Collman et al., 2009) showed that at higher concentration 
(approximately 10 µM and above), H2S binds to the iron center (Fe
2+) in the reduced active 
site and acts as an inhibitor of the enzyme as it competes with O2. The inhibitory effect of 
H2S on mitochondrial respiration has been well documented in various cell lines (Khan et al., 
1991; Thompson et al., 2003; Buckler, 2012). This inhibition is reversible because O2 can 
easily replace bound H2S; with Cox activity returning to its original levels within 10 - 30 min 
in vitro (Di Meo et al., 2011). Interestingly, Cox inhibition is pH-dependent (Nicholls and Kim, 
1982). It is actually suggested that acidosis shifts the balance of protonated (H2S) and 
deprotonated (HS-) forms in solution, and these two forms may have a different affinity for 
Cox (Szabo et al., 2014). This characteristic is of great importance as it suggests enhanced 
inhibitory effect in condition/sites with local acidosis.  
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2.2. Stimulatory effects of H2S on mitochondrial respiration 
Besides the ability of circulating oxidizers to consume and eliminate H2S, the main 
pathway of H2S catabolism operates in mitochondria. At nanomolar to low micromolar 
concentrations, sulfide can transfer electrons to coenzyme Q, which then follow the normal 
oxidative route to complex III and IV, activating mitochondrial respiration and ATP 
production (figure 8) (Goubern et al., 2007; Modis et al., 2013). Initial work utilizing 
colonocytes described that electron transfer from H2S to mitochondrial ETC implicates a 
sulfide oxidation unit (SOU) that consists of three enzymes: a sulfide quinone reductase, a 
dioxygenase and a sulfur transferase (Goubern et al., 2007). Oxidation of H2S by SOU 
produces thiosulfate (H2S2O3) by consuming an additional molecule of O2. 
                            
 
                                                                                                                                                                                                                                                                                                                           
Figure 8: Dual effects of H2S on the mitochondrial electron transport chain. The sulfide 
oxidation unit (SOU), which oxidizes two molecules of sulfide and uses one O2 molecule, 
releases thiosulfate and reduces quinone Q (yellow box a). Complex III accepts electrons 
from ubiquinone and drives them through complex IV (pink box b). Block c (green box) is 
constituted by the other enzymatic reactions reducing ubiquinone. Complex IV is the target 
of sulfide inhibition, becoming significant at concentrations of 10 µM and above, whereas 
SOU operates well below 10 µM concentration. Szabo et al., 2014. 
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 This nature of H2S serving as an ETC substrate is functionally comparable to TCA 
cycle-derived electron donors (NADH or FADH2), although the yield of sulfide in terms of 
electrons to be used by the ETC is relatively low (1 molecule of sulfide provides 1 electron, 
whereas NADH can donate 2 electrons and FADH2 2 electrons). Moreover, because of the 
additional O2 consumption implicated in the sulfide oxidation by SOU, the yield in energy per 
O2 consumed is low compared to NADH and FADH2 (Szabo et al., 2014). This process may 
have been the primordial version of energetic metabolism of deep-see living unicellular 
species that evolved billions of years ago (MacLeod et al., 1994). 
3. Biological functions  
H2S has specific physiological functions in different systems. In the nervous system, 
H2S exerts multifaceted effects by activating N-methyl-D-aspartate (NMDA) receptors 
(Kimura, 2002) and by directly increasing glutamate secretion (Garcia-Bereguiain et al., 
2008). In the endocrine system, H2S controls pancreatic insulin metabolism as well as 
glucose homeostasis (Ali et al., 2007). In the gastro-intestinal system, sulfate-reducing 
bacteria (SRB) present in the lumen of mice and humans can produce 0.2-3.4 mM H2S 
(Blachier et al., 2010), but the efficient sulfide oxidation to thiosulfate and sulfate by the 
colonic mucosa allows protection against high concentrations of H2S (Goubern et al., 2007). 
In the colon, H2S has been reported to have both pro and anti-inflammatory effects, to 
mediate smooth muscle relaxation and epithelial secretory function, and to modulate 
nociception (Medani et al., 2011).  
The most described physiological effects of H2S are in the vascular system. H2S-
induced vasorelaxation has been demonstrated in numerous types of blood vessels from 
different species (Wang, 2012). H2S regulates the vascular tone mainly by opening ATP-
sensitive potassium (KATP) channels (Cheng et al., 2004). As illustrated in figure 9, KATP 
activation leads to hyperpolarization of vascular smooth muscle cells, causing vasodilation 
by reducing voltage-gated Ca2+ influx. KATP channels are composed of pore-forming (Kir 6.X) 
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and sulfonylurea receptor (SUR) subunits. Compiling evidence suggests that SUR receptors 
are the sites of modulation by H2S: K
+ currents generated by expression of Kir subunits in 
the absence of SUR receptors are insensitive to H2S (Jiang et al., 2010). Earlier data 
indicating that H2S increases the open probability of KATP channels in excised membrane 
patches (independently of ATP levels) supports a direct mechanism of H2S action (Yang et 
al., 2005). Furthermore, alkylation or oxidation of cysteine residues located on the 
extracellular face of the SUR1 protein prevents regulation by H2S (Jiang et al., 2010).  
 
 
 
                                              
 
Figure 9: The KATP channel comprises four channel subunits (Kir 6.X) associated to four 
sulfonylurea receptors (SUR). The channel is activated by H2S through modification of SUR 
cysteine residues. Vascular KATP channels opening leads to hyperpolarization and relaxation 
of vascular smooth muscles, which induces vasorelaxation and lowers the blood pressure.  
Adapted from (Peers et al., 2012). 
 
A NO-dependent vasoactive mechanism has also been proposed, conferring a dual 
modulation of vascular tension to H2S. Indeed, several studies reported that H2S may 
promote (Hosoki et al., 1997; Predmore et al., 2011) or inhibit (Geng et al., 2007; Kubo et 
al., 2007) NO production, leading to either a synergistic or an antagonistic relaxation of 
blood vessels.  
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Intriguingly, different vascular tissues show different sensitivities to H2S. For example, 
it has been reported that H2S relaxes small mesenteric arteries six times more efficiently 
than the aorta (Cheng et al., 2004). The mechanisms for the differential vasodilatory effects 
of H2S may be related to the tissue-specific distribution of its molecular targets. In addition, 
different type of blood vessels face different sheer stress levels, possess different cellular 
and connective components, and/or have a different stiffness, which can further affect the 
biological response to H2S (Wang, 2012). Finally, the O2-dependent sensitivity of blood 
vessels to H2S must be highlighted. Indeed, KATP subunits expression in human myocardium 
is inversely correlated with venous pO2 and culturing myocytes under hypoxic conditions 
results in HIF-1-dependent upregulation of the KATP channel (Raeis et al., 2010). It was also 
reported that H2S induces vasorelaxation much faster in a hypoxic compared to normoxic 
environment (Koenitzer et al., 2007). 
4. Pre-clinical studies on the role of H2S in cancer  
Many studies have focused on the potential role of H2S in colon cancer development. 
Analysis of human colon cancer biopsies and patient-matched normal mucosa revealed the 
selective upregulation of H2S-producing enzyme CBS, resulting in an increased rate of H2S 
production in cancer cells (Szabo and Hellmich, 2013). Using small hairpin ribonucleic acid 
(shRNA) -mediated silencing or pharmacological inhibition of CBS, authors of this study 
demonstrated that H2S promotes HCT116 human colon cancer cells proliferation because it 
stimulates bioenergetics (both OXPHOS and glycolysis). Effect of H2S on glycolysis was 
attributed to an increase in the catalytic activity of the enzyme GAPDH via sulfhydratation 
(Mustafa et al., 2009). Treatment of nude mice with a specific CBS inhibitor attenuated the 
growth of patient-derived colon cancer xenografts. It was also suggested that CBS-derived 
H2S can promote vasorelaxation and angiogenesis, thereby providing tumors with blood and 
nutrients and increasing tumor invasion capacity (Szabo and Hellmich, 2013). A summary of 
the proposed mechanisms for H2S induced colon cancer growth is presented in figure 10.   
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Figure 10: Overexpression of CBS in cancer cells leads to H2S overproduction. H2S acts as 
an electron donor and stimulates mitochondrial electron transport. In addition, H2S increases 
glycolysis by increasing the catalytic activity of the glycolytic enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). These autocrine effects have been suggested to 
increase proliferation, migration and invasion. By diffusing into the surrounding tissue, H2S 
further stimulates angiogenesis and acts as a vasodilator, thereby also promoting the supply 
of blood and nutrients to the tumor. Zsabo and Hellmich, 2013. 
 
 
In another study, exogenous administration of a fast H2S-releasing inorganic donor 
(NaHS) also induced the proliferation of HCT116 human colon cancer cells in a 
concentration-dependent manner, with the optimal proliferative concentration identified to be 
200 µM. Authors suggested that this effect might be mediated by increasing Akt and ERK 
phosphorylation and by inhibiting the cyclin-dependent kinase inhibitor P21, resulting in an 
increased proportion of cells in S phase (Cai et al., 2010).  
Unexpectedly, Wu et al. (Wu et al., 2012) reported opposite results regarding the effect 
of H2S on colon cancer cell proliferation. In the same cancer cell line (HCT116) but with 
higher NaHS concentrations (400 µM-1 mM), H2S inhibited cell proliferation through 
activation of the AMPK pathway. Conflicting conclusions are probably related to the known 
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bell-shaped dose-response curve of H2S, where lower levels of H2S exert physiological and 
cytoprotective effects and higher local H2S concentrations promotes cytotoxicity (Wang, 
2012). 
A few years ago, a group characterized a novel, water-soluble, slow-releasing H2S 
compound (GYY4137), and evaluated its use as an anticancer agent in two studies. In the 
first study, they showed that compared to NaHS that releases H2S within minutes, GYY4137 
releases H2S much slower, with H2S concentrations remaining higher than baseline for up to 
7 days in the culture medium (figure 11) (Lee et al., 2011).          
 
      
         
Figure 11: Differential H2S-releasing kinetics of NaHS and GYY4137. Concentrations of H2S 
were assessed spectrophotometrically using a methylene blue-based method. ZYJ1122 is a 
control for GYY4137 lacking sulfur and unable to produce H2S. Lee et al., 2011. 
 
 
In the first study, the single exposure of MCF-7 (breast adenocarcinoma), MV4-11 
(acute promyelocytic leukemia) and HL-60 (myelomonocytic leukemia) tumor cells to 400 
µM NaHS did not increase or decrease cancer cell proliferation after 5 days, whereas 
GYY4137 caused a concentration-dependent reduction in cancer cell proliferation and 
survival, with cell cycle arrest in the G2/M phase and promotion of apoptosis (Lee et al., 
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2011). More recent data indicate that continuous and low exposure to H2S was necessary to 
selectively target cancer cells. Replacement of NaHS (5-20 µM) every 2 hours for 5 days 
significantly decreased cell viability and had a more important effect on malignant compared 
to non-malignant cells (Lee et al., 2014). These authors further suggested that H2S had 
combined effects on glycolysis and pHi regulators. It was proposed that H2S concomitantly 
increases metabolic acid production through glycolysis and impairs pHi regulation, resulting 
in cytotoxic intracellular acidification (Lee et al., 2014) (figure 12).  
       
              
 
Figure 12: H2S promotes an influx of glucose and triggers enhanced glycolysis in cancer 
cells. Overproduction of lactate coupled with an impaired activity of pH regulators results in 
the accumulation of acid and in a reduction of pHi. pHi then serves as a stimulus to induce 
cancer cell death. AE: anion exchanger, GLUT: glucose transporter, HK: hexokinase, NHE: 
sodium/proton exchanger, PFK: phosphofructokinase, PK: pyruvate kinase. Lee et al., 2014. 
 
Finally, although the anticancer properties of NaHS have not been studied in vivo, 
GYY4137 administered daily to nude mice caused a dose-dependent reduction in the 
progression of two human leukemia tumor models (Lee et al., 2011). 
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5. H2S in combination with radiotherapy 
In 2011, Zhang and colleagues investigated whether H2S could influence hypoxia-
induced radioresistance in vitro (Zhang et al., 2011). Experiments showed that, when 
hypoxic human hepatoma HepG2 cells were treated with 50 or 100 μM NaHS before 
irradiation, cells became more radioresistant so that survival was enhanced. 
Radioresistance was limited to lower concentrations of NaHS (25-100 μM). When the con-
centration of NaHS exceeded 200 μM, its protective effect was lost and the treatment 
became cytotoxic. This phenomenon is consistent with the fact that H2S has opposite 
actions depending on its concentration and the time of application. Authors of the study 
hypothesized that H2S may induce the radioresistance of hypoxic tumor cells via activation 
of K+ATP channels and inhibition of Ca
2+ flux. This study suggested that H2S (derived from 
NaHS) may confer intrinsic radioresistant properties to cancer cells. 
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Chapter 2 Aims of the thesis 
 
 
This thesis pursued a dual objective. In one part, the aim was to experimentally validate the 
hypothesis suggesting that rewiring glucose metabolism benefits to both energetic and 
biosynthetic demands of cancer cells. Indeed, enhanced glycolysis potentially allows fast 
ATP production and provides carbon intermediates that can be shunted to anabolic 
pathways. For the purpose, we compared the metabolic profile of different cancer cell lines 
and analyzed their intracellular ATP concentration and DNA synthesis rate. We paid 
attention to how enhanced glycolysis promotes cancer cell proliferation, as it could help to 
identify new mechanisms by which glycolysis-targeting drugs impair tumor growth. The 
pentose phosphate pathway (PPP) was specifically analyzed because it uses glycolytic 
intermediates to supply cells with nucleotide precursors and NADPH, a crucial reductant in 
anabolic processes. Furthermore, we aimed to study the therapeutic relevance of these 
findings. Dichloroacetate (DCA) was used because it had already demonstrated interesting 
anticancer properties in vitro and in vivo, and is currently tested in clinical trials. However, its 
mechanism of action, which globally consists in induction of apoptosis, has recently been 
questioned. We thus analyzed whether DCA interferes with the PPP in order to propose a 
new mechanism by which this promising molecule impairs tumor progression. 
 
The second part of this work focused on mitochondria as target for cancer therapy, 
especially in combination with radiotherapy (RT). Experimental evidence suggested that 
inhibition of O2 consumption may be the most effective way to reduce hypoxia, a major 
contributor to RT failure in the treatment of solid tumors. Unfortunately, inhibition of tumor 
cell O2 consumption in combination with RT has attracted only little interest in the clinics, as 
compared to provascular approaches. In this context, we hypothesized that hydrogen sulfide 
(H2S), the most recently identified gasotransmitter in mammals, could radiosensitize solid 
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tumors. Indeed, H2S is known to primarily target the mitochondrial ETC. Moreover, it is 
implicated in the vasorelaxation of blood vessels, which could also improve tumor 
oxygenation. We therefore used sodium hydrosulfide (NaHS) as a H2S donor, and 
questioned whether it could potentially alleviate tumor hypoxia and consequently 
radiosensitize experimental tumors by an oxygen effect. To help understand the existing 
conflictual data pertaining to the implication of H2S in cancer progression, we also analyzed 
the effects of NaHS in monotherapy in vitro and in vivo. 
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Chapter 3 Glycolysis drives cancer cell proliferation  
 
 
 
Inhibition of the pentose phosphate pathway by dichloroacetate unravels 
a missing link between aerobic glycolysis and cancer cell proliferation 
 
Géraldine De Preter, Marie-Aline Neveu, Pierre Danhier, Lucie Brisson, Valéry 
L. Payen, Paolo E. Porporato, Bénédicte F. Jordan, Pierre Sonveaux and 
Bernard Gallez. Oncotarget. 2015; DOI: 10.18632/oncotarget.6272 
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Fig. S1. DNA synthesis is not correlated to intracellular ATP content in cancer cells. 
Measurements were performed after 24 h incubation in the presence of a culture medium 
containing only glucose as energetic fuel. Total ATP was quantified from lysed cells and 
normalized to protein content. Proliferation rates were analyzed by the incorporation of a 
nucleotid analog (5-bromo-2’-deoxyuridine [BrdU]). A non-significant correlation was found 
(p-value = 0.48, Pearson r = -0.35). Results are expressed as means ± SEM. 
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Fig. S2: Viability assays show no difference in the number of viable WT and ρ0 SiHa 
cancer cells. Viability assays were performed on wild-type (WT) and mitochondria-deficient 
(ρ0) SiHa cancer cells using trypan blue exclusion after 24 h incubation in the experimental 
medium (DMEM without glutamine, containing 4.5 g/L glucose supplemented with 10 % heat 
inactivated FBS and 1% penicillin-streptomycin. Results are expressed as means ± SEM. 
Two-sided t test. ns, non-significant.  
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Fig. S3: Treatment with the glycolysis inhibitor 2-Deoxy-D-glucose impairs 
proliferation of MDA-MB-231 cancer cells.  MDA-MB-231 cancer cells were exposed to 5 
mM 2-Deoxy-D-glucose (Sigma) during 48 h. Proliferation rates were analyzed by the 
incorporation of a nucleotid analog (5-bromo-2’-deoxyuridine [BrdU]) incubated during 4 h in 
the presence of the cells. Two-sided t test. ***p<0.001. Results are expressed as means ± 
SEM. 
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Fig. S4: Short-term lactate production measurements reveal that DCA is more effective 
in Warburg-phenotype cancer cells. Lactate production by MDA-MB-231 and SiHa cancer 
cells treated or non-treated with DCA 5 mM during 1 h. Results are expressed as the relative 
change in lactate concentration from baseline. 
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Fig. S5: DCA treatment does not induce cancer cell death. Viability assays using trypan 
blue exclusion were performed on MDA-MB-231 cancer cells (A) and SiHa ρ0 cancer cells 
(B) treated or non-treated with DCA 5 mM during 48 h. The absence of significant difference 
in viable cell number between treated and non-treated cells indicated that cell mortality was 
not induced by DCA treatment. Results are expressed as means ± SEM. Two-sided t test. 
ns, non-significant.  
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Fig. S6: Treatment with 6-AN impairs proliferation of SiHa ρ0 cancer cells.  SiHa ρ0 
cancer cells were exposed to 100 µM 6-AN during 48 h. Proliferation rates were analyzed by 
the incorporation of a nucleotid analog (5-bromo-2’-deoxyuridine [BrdU]) incubated during 4 h 
in the presence of the cells. Two-sided t test. ***p<0.001. Results are expressed as means ± 
SEM. 
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Chapter 4 Hydrogen sulfide donor potentiates radiotherapy 
 
 
 
 
 
 
A fast hydrogen sulfide-releasing donor increases the tumor 
response to radiotherapy 
 
 
Géraldine De Preter, Caroline Deriemaeker, Pierre Danhier, Lucie 
Brisson, Thanh Trang Cao Pham, Vincent Grégoire, Bénédicte F. 
Jordan, Pierre Sonveaux and Bernard Gallez. 
Molecular Cancer Therapeutics, 2016; DOI: 10.1158/1535-7163.MCT-
15-0691-T 
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Supplemental Fig. S1. Effect of the experimental conditions on cancer cells viability 
after OCR measurements. Viability of MDA-MB-231 and SiHa cancer cells was measured in 
vitro using trypan blue exclusion after OCR measurements. (A-B) Cancer cells treated with 
50 µM NaHS or vehicle (NaCl 0.9 %) in the presence of different pHe values. (C-D) Cancer 
cells treated with increasing NaHS concentration or vehicle in the presence of pHe = 6.5. No 
significant cell death was found in any of the experimental conditions. 
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Supplemental Fig. S2. Effect of the experimental conditions on cancer cells viability 
after proliferation measurements. Viability of MDA-MB-231 was measured in vitro using 
trypan blue exclusion after BrdU incorporation measurements. Cancer cells were treated with 
50 µM NaHS or vehicle (NaCl 0.9 %) in the presence of pHe = 6.5. No significant cell death 
was found in any of the experimental conditions. 
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Supplemental Fig. S3. Implication of ROS in the proliferative effects of NaHS. MDA-MB-
231 cancer cells were incubated with vehicle (NaCl 0.9 %), 50 µM NaHS alone or pre-treated 
with 3 mM N-acetyl cysteine (NAC, a ROS scavenger) before NaHS exposure in the 
presence of different pHe values during 4 hours. Proliferation rates were compared using 
BrdU incorporation measurements. No change was observed when cells were treated with 
NAC, suggesting that ROS were not implicated in the pro or anti-proliferative effects induced  
by NaHS. 
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Chapter 5 Discussion 
Principal findings 
We first sought to study the links between glucose metabolism, intracellular ATP 
content and the proliferation capacity in several cancer cell lines. Using biochemical 
methods allowing measurements of glycolysis efficiency and mitochondrial 
respiration, different metabolic profiles were drawn. By correlating the metabolic 
parameters with intracellular ATP content and DNA synthesis rate, we found that 
enhanced glycolysis is positively correlated to DNA synthesis. No significant 
correlation between glycolysis and ATP levels was found. We rather observed a 
negative trend between glycolysis efficiency and ATP. These results obtained using 
six different human and murine cancer cell types experimentally showed that 
glycolysis is a key factor directly contributing to cell proliferation, and confirmed the 
current hypothesis that its main role may not be dedicated to ATP production. In 
other words, this observation implies that other factors than ATP production are 
limiting for proliferating cancer cells. This was also showed by the use of 
mitochondria-deficient isogenic cancer cells exhibiting a glycolytic switch, associated 
with an increased DNA synthesis rate and a decreased total ATP pool.   
We therefore addressed the role of the PPP in linking enhanced glycolysis and 
proliferation in two human cancer cell lines. Experiments with a pharmacological 
inhibitor of the PPP suggested that this pathway is essential for optimal proliferation, 
especially in glycolytic cancer cells. This was confirmed with siRNAs targeting G6PD, 
the first and rate-limiting enzyme of the oxidative branch of the PPP.  
We finally identified that DCA, a promising molecule for the treatment of malignant 
lesions, decreases cancer cell proliferation in a glycolysis-dependent manner. 
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Altogether, we propose that a reduction in the glycolytic metabolism of glucose 
induced by DCA also decreases the PPP flux along with cellular proliferation.  
 
A second part of the thesis focused on a different approach to target metabolism for 
cancer therapy. Inhibition of mitochondrial respiration by H2S was hypothesized to 
increase the sensitivity of tumors to radiotherapy. Indeed, mitochondrial ETC 
complex IV is known as the primary target of H2S, and inhibition of O2 consumption 
appears to be a particularly effective strategy to alleviate hypoxia, a serious 
impediment in radiation efficacy. In vitro, we found that NaHS, a H2S donor, 
decreased mitochondrial respiration in a dose- and pH-dependent manner, which 
was associated with an increased glycolytic flux. Enhanced perfusion following NaHS 
delivery was also observed in vivo. Using electron paramagnetic resonance (EPR) 
oximetry, we reported a rapid increase in pO2 after NaHS administration in two 
human tumor models in mice. Furthermore, tumors irradiated after a single NaHS 
administration were more sensitive to irradiation. Radiosensitization was due to an 
oxygen effect as the increased growth delay was abolished when temporarily 
clamped tumors were irradiated. We finally aimed to investigate whether the H2S 
donor could have a direct effect on tumor growth. Chronic NaHS injections showed 
no significant impact on tumor growth curves in mice. We highlighted that pHe 
induced paradoxical responses to NaHS. An increased proliferation was found at 
alkaline pHe whereas a decreased proliferation was found at acidic pHe following 
exprosure of cancer cells to NaHS. This may, at least in part, explain why NaHS was 
found inactive in vivo. A summary of the findings on the use of the H2S donor in 
combination with radiotherapy or in monotherapy is provided in figure 13. 
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Figure 13: Principal findings obtained from the use of NaHS, a fast H2S-releasing 
donor, in our study. NaHS administration a few minutes before irradiation provided 
therapeutic benefit by alleviating tumor hypoxia. We suggested that the improved tumor 
oxygenation by H2S derived from NaHS at the time of irradiation resulted from an inhibition of 
the oxygen consumption by tumor cells and an increase in tumor perfusion. We highlighted 
that the inhibitory effect of NaHS on oxygen consumption was pHe- and dose-dependent. On 
the other hand, daily NaHS injection was found ineffective to control tumor xenografts in 
mice. Indeed, in vitro, it was found that NaHS induced opposite effects on tumor cell 
proliferation depending on the pHe.  
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Discussion and Perspectives 
 
1.  Glycolysis drives cancer cell proliferation  
 
1.1 In vitro characterization of bioenergetics and proliferation: limitations 
and perspectives 
Experiments that aimed to evaluate the metabolic parameters (glycolysis 
and OXPHOS activities), energy stores and proliferation capacities of cancer cells 
were performed separately. Indeed, technical procedures did not allowed 
concomitant measurements of all parameters. As examples, cell harvesting, cell lysis, 
and/or cell fixation were required depending on the experiment. It should therefore be 
noted that the multiple correlations between metabolic and proliferative patterns 
could thereby suffer from inevitable experimental bias. Concomitant analysis of the 
patterns at the same moment, in the same viable cells, would appear ideal. In fact, 
the most difficult would be to quantify intracellular ATP, which systematically includes 
extraction processes. Interestingly, a new technique that allows the rapid, direct 
measurement of the intracellular ATP content in living cells was reported. This 
original system relies on a protein transduction domain-conjugated luciferase (PTD-
Luc) that can penetrate the cell membrane without affecting its integrity or interfering 
with cellular metabolism (Lee et al., 2012).  
In this study, the efficacy of the conversion of glucose to lactate was used to 
compare the glycolytic activity between cell lines. This method offers the advantage 
to more closely reflect the glycolytic flux as compared to molecular biology 
approaches. Variation in mRNA content or protein expression is not always 
proportional to changes in enzyme/transporter activity, and much less to changes in 
metabolic flux (Moreno-Sanchez et al., 2014). Nevertheless, a significant limitation to 
the enzymatic determination of lactate/glucose ratio can be highlighted. Glucose is 
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the major source of lactate, but glutaminolysis may also significantly contribute to 
lactate production in cancer cells (Chapter 1 III.2). In our experimental conditions, 
metabolite analysis was performed on cells incubated for 24 hours without glutamine. 
Therefore, the contribution of glutamine to lactate production was considered to be 
negligible. It can be mentioned that the specific determination of the different sources 
of lactate can be achieved using isotope-labeling approaches that are more accurate 
to evaluate the fate of nutrients. 
1.2 Inhibition of the pentose phosphate pathway: implicated mechanisms 
and therapeutic potential  
The PPP is a glucose catabolic pathway that links glucose metabolism to 
nucleotide biosynthesis and NADPH production. This process provides two 
significant factors for tumor progression: biosynthetic precursors through the 
generation of R-5-P (nucleotide precursor) and NADPH (reductive equivalent for 
macromolecule synthesis) and antioxidant protection, involving the transfer of 
electrons from NADPH to thioredoxin/peroxiredoxin and glutathione systems.  
In our study, inhibition of the PPP was found following treatment of cancer 
cells with 6-aminonicotinamide (6-AN), siRNAs against G6PD and DCA. All 
treatments were associated with a reduced proliferation capacity in cancer cells. It 
would have been interesting to further investigate whether one (or both) of the above-
mentioned mechanisms is (are) predominantly implicated in the anti-proliferative 
effects of these treatments. In particular, this would have allowed to precisely 
understand how DCA affects cancer cell proliferation. Indeed, DCA when used at 
similar doses as the ones that we used in our study (5 mM) has also been described 
to induce ROS production (Stockwin et al., 2010). Decreased PPP flux by DCA could 
therefore account for a decreased biosynthetic capacity and/or a decreased 
protection against ROS. To investigate whether a reduction in R-5-P synthesis is 
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responsible for the inhibition of cancer cell proliferation by DCA, supplementation of 
culture media with nucleosides and ribonucleosides could have been tested (Frolova 
et al., 2011). Rescue using downstream products of the PPP would have further 
provided evidence that it is the nucleotide precursor shortage and not lower NADPH 
levels that is responsible for decreased cell proliferation. Conversely, incubation of 
cells with antioxidants would have underlined the antioxidant role of the PPP.   
While numerous glycolytic inhibitors are being investigated in humans, there 
is currently no inhibitor of the PPP in clinical trials, even though the PPP may be an 
attractive target. 6-AN has already been evaluated as an anticancer compound but 
was found to be neurotoxic at high doses and failed to demonstrate anticancer 
activity in well tolerated doses (Herter et al., 1961). 6-AN still remains under 
consideration as a potential radiosensitizer (Sharma et al., 2012; Manganelli et al., 
2013). Inhibition of the PPP or of G6PD may also enhance the sensitivity of cancer 
cells to chemotherapeutic agents known to induce genetic damage and to produce 
ROS (Jones and Schulze, 2012). A very interesting study screened small-molecule 
compound libraries and identified new human G6PD inhibitors with IC50 values < 4 
µM. One of the inhibitors reduced the proliferation of mammary carcinoma cells 
(Preuss et al., 2013). This will probably arouse the interest for the use of specific PPP 
inhibitors alone or as co-treatment in clinical cancer research. 
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2. Reversing the Warburg Effect with dichloroacetate 
2.1 Metabolic plasticity in MDA-MB-231 and SiHa cancer cells 
The Warburg hypothesis on the origin of cancer has been revisited and the 
environment of cancer cells (nutrients, O2, pH, hormones, drugs…) is now well 
recognized to play a determining role on tumor bioenergetics. By showing that DCA 
increases glucose oxidation (which only occurs in functional mitochondria) in lung, 
brain and mammary cancer cells, Bonnet and colleagues (Bonnet et al., 2007) 
provided evidence that aerobic glycolysis, a well-established, metabolic signature of 
many cancer cells, is most often reversible rather than a general consequence of 
permanent mitochondrial damage.  
Our group studied the glucose consumption of MDA-MB-231 and SiHa 
cancer cells under hypoxia (1% O2) and normoxia (21 % O2) in order to investigate 
the metabolic plasticity of these cells. MDA-MB-231 cancer cells consumed glucose 
at a higher rate than SiHa in hypoxia, but both cell lines showed a decreased glucose 
consumption when the O2 supply was increased (unpublished data); suggesting a 
Pasteur Effect even in highly glycolytic cells. In another study, our group also showed 
that increased oxygenation induced by carbogen breathing in MDA-MB-231 and SiHa 
tumor xenografts led to a decreased uptake of 18F-FDG (18F fluorodeoxyglucose), a 
glucose analog used in positron emission tomography (PET) studies, in both tumor 
models (Neveu et al., 2015). These observations suggest that, in our tumor models, 
glycolysis can also be altered by promoting OXPHOS. 
2.2 Differential response to DCA  
Preclinical studies with DCA have shown variable responses between 
cancer cells (Chapter 1 II.3.2). This emphasizes the need for biomarkers that can 
predict the therapeutic response to PDK inhibitors. Both cancer cells lines used here 
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(MDA-MB-231 and SiHa) can remodel their glucose metabolism in response to 
external stimuli, thus displaying metabolic flexibility. However, short-term lactate 
production measurements showed that DCA decreased glycolysis in MDA-MB-231 
cancer cells. This resulted in a decreased proliferation in this cell line compared to 
SiHa. The isogenic comparison of oxidative SiHa cancer cells versus SiHa with a 
high glycolytic activity further validated that glycolytic cells are more sensitive to DCA 
than oxidative ones. These findings are in agreement with a recent study showing 
that glycolytic, metastatic prostate cancer cells are DCA-responsive, whereas their 
isogenic less glycolytic counterparts are unresponsive (Kailavasan et al., 2014). It 
also supports that the activity of DCA is enhanced when glycolysis is upregulated in 
cancer cells (Stockwin et al., 2010). Nonetheless, it should be highlighted that 
observations from another study led to the opposite conclusion (Higgins et al., 2009).  
One could simply suggest that the anti-proliferative effects of DCA are 
directly related to the variable reliance of cells on glycolysis-branched anabolic 
processes. It is our opinion that it is not the primary cause of the different responses 
to DCA. Because short-term evaluation (1 hour) of DCA efficacy showed that DCA 
inhibits glycolysis in responsive cells but not in resistant ones, we rather suggest that 
the primary factor in DCA efficacy is its capability to efficiently inhibit PDK, resulting in 
tumor cell metabolism rewiring and altered cell proliferation. Some hypotheses can 
be put forward to try understanding how cellular singularities, sometimes linked to the 
metabolic profile, can influence the response to DCA: 
 Access to intramitochondrial PDK  
Dichloroacetate is ionized and cannot pass through the plasma membrane by 
diffusion. To the best of our knowledge, there have been only two reports on the 
transport of dichloroacetate into mammalian cells. The first one identified that 
monocarboxylate transporters (MCTs) facilitate the uptake of DCA into hepatocytes 
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and Ehrlich-Lettre tumor cells (Jackson and Halestrap, 1996). The second one 
showed that the sodium-coupled MCT (SMCT) SLC5A8 transports DCA very 
effectively with a higher affinity compared to MCTs (Babu et al., 2011). This 
transporter is sometimes found to be silenced in tumor cells via epigenetic 
mechanisms, which was suggested to explain why high millimolar concentrations of 
DCA are needed to cause a therapeutic response in vitro. We could therefore 
hypothesize that the differential sensitivities of cancer cells to DCA could be related 
to their relative expression of MCTs, and, especially, of SLC5A8, and that evaluation 
of the differential protein expression profiles in glycolytic and oxidative cancer cells 
may be relevant. In this regard, it has already been reported that the expression of 
MCTs differs depending on the metabolic phenotype of cancer cells (Sonveaux et al., 
2008). Although not yet investigated, the level of expression of mitochondrial 
pyruvate carriers (MPCs) may also impact the response of cells to DCA. MPCs could 
indeed determine the rate of penetration of DCA inside the mitochondrial matrix 
(Schell et al., 2014). 
 PDK isoforms 
The four PDK isozymes vary considerably in their sensitivity to inhibition by DCA. 
PDK2 is the most sensitive, PDK3 the most resistant, and the sensitivities of PDK1 
and PDK4 are intermediate. On the other hand, each PDK isoform has its own 
specific activity. Most active isoenzyme PDK3 is 25-fold more active than the least 
active PDK2 (Bowker-Kinley et al., 1998). Therefore, a low affinity of DCA for PDK3 
may be sufficient to alleviate PDH inhibition because of the high potency of PDK3 to 
impair PDH function. In this regard, analysis of the expression pattern of PDK 
isoforms between cell lines may be informative of the response to DCA, but specific 
activities should not be underestimated. 
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 DCA biotransformation 
DCA is eliminated mainly through glutathione transferase zeta 1 (GSTZ1)-catalyzed 
dechlorination to glyoxylate, an intermediate in the biotransformation of DCA to 
oxalate, CO2, and glycine (Li et al., 2011). Many cancer cell lines do express GSTZ1, 
including SiHa, at relatively different levels (www.proteinatlas.org)1. Correlating 
GSTZ1 expression and DCA efficacy between cancer cells could give new insights 
on the role of DCA elimination in the therapeutic response. Because GSTZ1 
catalyzes DCA biotransformation through a glutathione (GSH)-dependent mechanism 
(Board and Anders, 2005), comparison of GSH levels between cancer cells may also 
be relevant. 
2.3 To what extend can these in vitro findings anticipate the in vivo 
situation? 
In vitro analyses of cancer cell metabolism undoubtedly help demystifying 
its complex implications in cell proliferation and survival. It considerably helps 
identifying specific pathways or targets for future therapeutic approaches. It also 
contributes to the comprehension of drug resistance. However, it is clear that in vitro 
and in vivo environments have little in common. Compared to the artificial culture 
conditions, tumors experience constant changes in many factors, such as 
oxygenation, pHe, and nutrients availability. 
In vitro, we have shown that low millimolar concentrations of DCA decrease 
glycolysis along with the PPP flux, thereby limiting cancer cell proliferation. It should 
be mentioned that, even if glucose seems preferentially used as a source of energy 
and building blocks by tumor cells, glutamine and fatty acids can also significantly 
contribute to tumor growth. Consequently, inhibition of glycolysis by DCA could 
potentially be compensated by these alternative sources (metabolic flexibility). 
                                                          
1
 Web site visited on November the 4
th
, 2015 
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Moreover, expression and activity of PDK isoforms are sensitive to environmental 
stimuli. Metabolic stress conditions, such as starvation, fasting, and glucose 
deprivation can, for example, induce PDK4 expression (Hsieh et al., 2008). 
Therefore, it is difficult to anticipate whether our in vitro observations, obtained in 
artificial culture conditions with glucose as main source of energy, are also found in 
vivo.  
Human cancers also frequently display substantial intra-tumor 
heterogeneity in virtually all phenotypic features, including bioenergetics (Marusyk 
and Polyak, 2010). As different metabolic profiles can be exhibited by different tumor 
cells subpopulations, some tumor cells (oxidative) may be resistant while others 
(glycolytic) may be sensitive to DCA. Efficacy of DCA in vivo may therefore depend 
on the relative prevalence of oxidative vs. glycolytic cells within a given tumor. 
 
To study the metabolic and proliferative effects of DCA at clinically relevant 
doses in vivo, sensitive methods are required. Hyperpolarized nuclear magnetic 
resonance (NMR) tracers can increase the sensitivity of 13C magnetic resonance 
spectroscopy and allow non-invasive and real-time assessment of metabolic fluxes in 
vivo. Increasing the polarization of a particular compound, which determines the 
strength of the MR signal, can be achieved by dynamic nuclear polarization (DNP). 
This technique consists in the transfer of high electron spin polarization to nuclear 
spins via microwave irradiation in a strong magnetic field and at cryogenic 
temperature (Schroeder et al., 2011; Mignion et al., 2014). Recently, glycolysis in 
murine lymphoma and lung tumors was monitored by measuring the conversion of 
hyperpolarized glucose to lactate (Rodrigues et al., 2014). Production of 6-
phosphogluconate (6-PG) in the oxidative branch of the PPP was also detected 
suggesting that PPP evaluation is feasible with this method. The use of 
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hyperpolarized NMR tracers would therefore be of great utility to investigate whether 
low dose DCA (≤ 25 mg/kg orally, as tolerated in patients) interfere with glycolysis 
and PPP activities in mice. Indeed, such DCA concentrations may induce relatively 
small changes in metabolic fluxes. On another hand, PET in association with 
thymidine-analog tracers would allow studying changes in DNA synthesis in response 
to DCA. Early clinical data with 18F-FLT (18F-labeled 3’- deoxy-3’-fluorothymidine) 
demonstrated that its uptake correlates well with in vitro measurements of 
proliferation (Bading and Shields, 2008).  
2.4 Perspectives on the clinical use of DCA in cancer therapy 
When analyzing published results pertaining to clinical trials of oral DCA in 
cancer patients, DCA has proven encouraging in terms of tumor stabilization. 
However, like with other glycolysis inhibitors, chronic DCA treatment was associated 
with toxicity in several patients (Chapter 1 II.3.2.2). A major issue is dose-dependent 
neuropathy caused by oxidative stress in the peripheral nerves. For optimal 
therapeutic benefits, markers of response should be investigated. This would allow 
selecting responsive patients. We and others have highlighted that glycolytic cancer 
cells may be more sensitive to DCA. Intensity of incorporation of 18F-FDG, which is 
already used for diagnostic and monitoring purposes in the clinics, could therefore be 
indicative of the response to DCA in vivo, even though the degree of utilization of 
glycolysis and OXPHOS by cancer cells cannot be evaluated with this technique 
alone. Accurate and sensitive methods allowing the determination of predominant 
energetic pathways within a tumor are still lacking, and implementation of such 
methods in the clinics would undoubtedly help choosing the adequate therapeutic 
approach for each patient.  
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Preclinical studies have linked the sensitivity of cancer cells to DCA to the 
presence of specific transporters and PDK isoforms. These findings should also be 
considered. 
Like other groups previously, we have shown that low millimolar 
concentrations of DCA reduce cancer cell proliferation without altering cell survival. 
Because cytostatic effects may not be sufficient to provide a significant therapeutic 
gain or because they may be balanced by compensatory processes, we support the 
current view consisting in the use of DCA in combination therapy. One promising 
association is DCA and metformin. Metformin has been used for a long time as 
antidiabetic drug and has more recently been shown to display anticancer effects by 
targeting mitochondrial ETC complex I. Preclinical data are available and suggest 
that a co-treatment with DCA and metformin results in synergistic anticancer effects 
(Choi and Lim, 2014; Haugrud et al., 2014)  
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3. H2S as a new radiosensitizer 
3.1 Effects of NaHS on the oxygen consumption of cancer cells: a need for 
in vivo validation 
Our in vitro experiments emphasized that O2 consumption inhibition by H2S 
is pH-dependent, which is of major importance regarding the fact that acidic regions 
are commonly found in solid tumors. Thus, NaHS could more potentially target O2 
consumption in tumors than in healthy tissues. Nevertheless, we also showed that a 
sufficient NaHS concentration (50 µM) was needed to induce significant effects. 
Further studies on O2 consumption in vivo are therefore mandatory. It would 
unequivocally provide evidence that a decreased O2 consumption by tumor cells is 
implicated in the observed increase in pO2 following systemic NaHS injection (100 
µmol/kg I.P.). Hence, comparison with healthy tissues, such as adjacent muscle 
tissue, could confirm the expected tumoral selectivity of H2S. 
Intratumoral H2S concentration could also be measured to test whether 
sufficient H2S is present to inhibit O2 consumption. Low H2S concentrations (< 10 µM) 
are known to increase mitochondrial oxidative activity, which could lead to 
unfavorable pO2 variations. Obtaining accurate and reliable measurements of 
biologically free H2S is laborious. Sulfide ion selective electrodes have however 
shown efficacy to detect H2S levels in biological samples, but they may suffer from 
limited sensitivity. H2S can be more sensitively measured by reversed-phase high 
liquid performance chromatography (RP-HPLC) coupled with fluorescence detection. 
This method, which requires sulfide derivatization, has been suggested to be suitable 
for accurate quantitative measurement of free H2S in multiple biological samples 
(Shen et al., 2011). 
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3.2 NO and H2S: two radiosensitizing molecules with similar and selective 
modes of action in tumors 
Our group has previously contributed to the demonstration that NO can 
radiosensitize solid tumors through different mechanisms (Chapter 1 III.3.3). We now 
provide a proof of concept that H2S, the last identified endogenous gasotransmitter to 
date, shares this therapeutic potential. Due to the fact that NO and H2S have various 
similar properties, it appears important to compare their radiosensitizing effects 
(Table 2).  
Interestingly, increasing evidence suggests that H2S and NO may 
reciprocally regulate their production and biological effects. H2S donors were indeed 
reported to induce eNOS activity through phosphorylation processes, subsequently 
increasing NO production (Kolluru et al., 2013). Reciprocally, NO donors can up-
regulate the expression and activity of H2S-producing enzymes. Interestingly, 
potential synergistic effects of NO and H2S in controlling the vascular function have 
also been highlighted (Hosoki et al., 1997). H2S/NO relationships are complex and 
still poorly defined, especially in the context of tumors, but one cannot exclude that 
H2S enhances the radioresponse through NO-dependent pathways, and vice-versa. 
It must be finally added that effects of NaHS on the cell cycle may also 
contribute to the observed radiosensitization process. Indeed, cell cycle phases can 
influence cellular responses to radiations (Sinclair, 1968). In published studies, H2S 
has been reported to induce a cell cycle arrest in S or G2/M phases depending on its 
mode of administration and concentration (Cai et al., 2010; Lee et al., 2011). 
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Table 2: Comparison of the radiosensitizing effects, intrinsic tumor selectivity and 
mode of administration of NO and H2S. 
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3.3 Clinical applicability of H2S in cancer therapy 
Safety of inhaling H2S gas is a key issue, and inhaled H2S has been 
associated with industrial and environmental risk (Wang, 2012). Inhalation of H2S has 
however been attempted in animal studies to induce suspended animation, a 
hibernation-like state. Indeed, in their pioneering study, Blackstone and colleagues 
(Blackstone et al., 2005) showed that awaken mice exposed to sub-toxic gaseous 
H2S concentrations (20-80 ppm) dose-dependently decreased their O2 
consumption. This fall in metabolic activity was associated with bradypnea and 
consecutive hypothermia. Upon H2S removal, these effects were completely reversed 
and animal functions rapidly returned to normal. Several differences between smaller 
and bigger animals may however considerably influence the hypometabolic 
responses to H2S. First, difference in surface area-to-mass ratios may render larger 
animals more resistant to temperature changes. Second, higher H2S concentrations 
may be required to induce a hypometabolism in larger animals and in humans 
(Wang, 2012). This approach could be problematic or even dangerous considering 
the toxicological profile of H2S at high concentrations. Therefore, inhalation of H2S 
gas has not been clinically tested yet. 
Comparatively, injectable H2S-releasing molecule could be more safe and 
suitable to treat cancer, especially with radiotherapy. In particular, fast and high H2S 
release is preferred. Indeed, increased tumor oxygenation is required only at the time 
of irradiation. In addition, regarding the paradoxical effects of the gas on 
mitochondrial ETC depending on local concentration, high H2S delivery is needed. It 
is important to note that sodium sulfide (Na2S), a H2S-releasing inorganic salt similar 
to NaHS, has already been evaluated in patients. In a clinical trial, it was aimed to 
determine whether IK-1001 (Na2S administered as an isotonic solution) was safe and 
if it could reduce damage caused by severe types of heart attacks (NCT01007461). 
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Unfortunately, this study has been withdrawn prior to enrollment in 2015. Withdrawal 
was due to company decision but was not safety-related. Another phase 1 study was 
launched to assess the pharmacokinetics of IK-1001 in healthy volunteers as well as 
in subjects with varying degrees of impaired renal function (NCT00879645). This 
study was interrupted in 2015 because of the inability to develop a rapid and reliable 
assay to detect sulfide concentration.  
A group recently reported a promising strategy for targeted H2S delivery to 
the heart in order to limit myocardial ischemia-reperfusion injury (Chen et al., 2014). 
This novel approach is based on H2S-filled microbubbles that, when injected 
systematically, are confined to the vasculature due to their size. With judicious 
application of ultrasound (US) energy, H2S can then be efficiently delivered to the 
targeted tissue through the process of sonoporation. Microbubble ultrasound contrast 
agents (MCA’s) are becoming increasingly popular for targeting drugs and genes to 
malignant tissues (Sirsi and Borden, 2012). H2S-filled microbubbles are thus 
promising as they could potentially reduce off-target effects and increase the 
therapeutic drug index of H2S. 
            
   
Figure 14: Microbubble ultrasound contrast 
agents (MCA’s) injected in the blood circulation 
are confined into the vasculature. The physical 
response of microbubbles to an ultrasound field 
can mechanically perturb blood vessel walls 
and cell membranes, enhancing drug 
permeability into tissues, such as malignant 
tissues. 
Sirsi and Borden, 2012. 
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4. General conclusion 
  
The present study emphasized the therapeutic potential of targeting cancer cell 
metabolism. We showed that compounds inhibiting either aerobic glycolysis or 
mitochondrial respiration provided therapeutic gain. We highlighted that metabolism-
targeting compounds may often benefit from the association with other therapies. 
Indeed, inhibition of cancer cell proliferation with tolerable DCA concentrations may 
have limited efficacy in patients. Moreover, this effect may be compensated by tumor 
cells metabolic plasticity. H2S, a mitochondrial inhibitor with multiple biological 
functions was found ineffective to treat tumors in mice, but enhanced tumor growth 
delay when associated with radiotherapy. In terms of toxicity and efficacy, further 
preclinical and clinical research on the inhibition of metabolic pathways in 
combination therapy would therefore likely provide significant advances for optimal 
cancer management. 
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